e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD)
A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands)
Source:
Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Session:
Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Session type:
Thematic Poster Session
Number:
774
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands). Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD). Eur Respir J 2007; 30: Suppl. 51, 774
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Elevated alveolar antioxidant levels in chronic fibrosing interstitial lung diseases
Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Year: 2008
Increased CCL18 production in interstitial lung diseases is associated with fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 38s
Year: 2004
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
COPD is associated with reduced pulmonary interstitial expression of pentraxin-3
Source: Eur Respir J 2012; 39: 830-838
Year: 2012
Increasing oxidative stress and inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD) and their association with lung function
Source: Annual Congress 2012 - The smoking gun in COPD biology
Year: 2012
Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
How systemic inflammatory diseases affect the lung
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020
Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 106s
Year: 2002
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Increased lung apoptosis and expression of ceramide in subjects with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2009 - COPD: basic science and clinical studies
Year: 2009
High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept